Pliant Therapeutics Inc PLRX.OQ PLRX.O is expected to show no change in quarterly revenue when it reports results on May 5 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Pliant Therapeutics Inc is for a loss of 72 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 11 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 0.6% in the last three months.
Wall Street's median 12-month price target for Pliant Therapeutics Inc is $3.00, above its last closing price of $1.62.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.98 | -0.98 | -0.82 | Beat | 16.6 |
Sep. 30 2024 | -0.96 | -0.97 | -0.95 | Beat | 2 |
Jun. 30 2024 | -0.83 | -0.85 | -0.92 | Missed | -8.4 |
Mar. 31 2024 | -0.75 | -0.77 | -0.78 | Missed | -1.1 |
Dec. 31 2023 | -0.77 | -0.81 | -0.69 | Beat | 15.2 |
Sep. 30 2023 | -0.76 | -0.77 | -0.70 | Beat | 9.7 |
Jun. 30 2023 | -0.72 | -0.71 | -0.70 | Beat | 1.9 |
Mar. 31 2023 | -0.65 | -0.67 | -0.67 | Met | -0.2 |
This summary was machine generated May 2 at 11:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。